![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BCAN |
Gene summary for BCAN |
![]() |
Gene information | Species | Human | Gene symbol | BCAN | Gene ID | 63827 |
Gene name | brevican | |
Gene Alias | BEHAB | |
Cytomap | 1q23.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q96GW7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
63827 | BCAN | P2T-E | Human | Esophagus | ESCC | 7.52e-23 | 7.50e-01 | 0.1177 |
63827 | BCAN | P56T-E | Human | Esophagus | ESCC | 1.10e-03 | 7.37e-01 | 0.1613 |
63827 | BCAN | P76T-E | Human | Esophagus | ESCC | 1.96e-05 | 4.40e-01 | 0.1207 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00215436 | Esophagus | ESCC | pallium development | 94/8552 | 169/18723 | 5.79e-03 | 2.14e-02 | 94 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCAN | SNV | Missense_Mutation | novel | c.2149N>G | p.Arg717Gly | p.R717G | Q96GW7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
BCAN | SNV | Missense_Mutation | c.739G>C | p.Asp247His | p.D247H | Q96GW7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
BCAN | SNV | Missense_Mutation | c.1561C>T | p.Pro521Ser | p.P521S | Q96GW7 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
BCAN | SNV | Missense_Mutation | c.748N>C | p.Cys250Arg | p.C250R | Q96GW7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
BCAN | SNV | Missense_Mutation | c.593N>A | p.Gly198Glu | p.G198E | Q96GW7 | protein_coding | deleterious(0.01) | possibly_damaging(0.843) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
BCAN | SNV | Missense_Mutation | c.2059T>G | p.Phe687Val | p.F687V | Q96GW7 | protein_coding | tolerated(0.65) | benign(0.015) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BCAN | SNV | Missense_Mutation | c.935N>A | p.Arg312His | p.R312H | Q96GW7 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-E2-A15D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
BCAN | SNV | Missense_Mutation | novel | c.40N>A | p.Leu14Met | p.L14M | Q96GW7 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
BCAN | SNV | Missense_Mutation | novel | c.2362G>T | p.Val788Leu | p.V788L | Q96GW7 | protein_coding | deleterious(0.01) | possibly_damaging(0.754) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BCAN | SNV | Missense_Mutation | rs372404921 | c.485N>A | p.Arg162Gln | p.R162Q | Q96GW7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |